CANNASSURE THERAPE

The current price of CSURE-M is 1326 ILA — it has increased by 10.04% in the past 24 hours.

Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange CANNASSURE THERAPE stocks are traded under the ticker CSURE-M.

CSURE-M stock is 9.17% volatile and has beta coefficient of 0.64. Check out the list of the most volatile stocks — is CANNASSURE THERAPE there?

Yes, you can track CANNASSURE THERAPE financials in yearly and quarterly reports right on TradingView.

CSURE-M stock has risen by 21.76% compared to the previous week, the month change is a 30.38% rise, over the last year CANNASSURE THERAPE has showed a 230.67% increase.

CSURE-M net income for the last quarter is ‪−1.23 M‬ ILS, while the quarter before that showed ‪−557.00 K‬ ILS of net income which accounts for −120.65% change. Track more CANNASSURE THERAPE financial stats to get the full picture.

No, CSURE-M doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.

Like other stocks, CSURE-M shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CANNASSURE THERAPE stock right from TradingView charts — choose your broker and connect to your account.

CSURE-M reached its all-time high on Apr 9, 2024 with the price of 1327 ILA, and its all-time low was 291 ILA and was reached on Nov 26, 2023.
See other stocks reaching their highest and lowest prices.

As of Apr 28, 2024, the company has 2.00 employees. See our rating of the largest employees — is CANNASSURE THERAPE on this list?

Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CANNASSURE THERAPE technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CANNASSURE THERAPE stock shows the strong buy signal. See more of CANNASSURE THERAPE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CANNASSURE THERAPE EBITDA is ‪3.06 M‬ ILS, and current EBITDA margin is 27.79%. See more stats in CANNASSURE THERAPE financial statements.